Abstract: A non-liquid vaccine composition including one or more antigen component(s); a pharmaceutically acceptable non-liquid adjuvant therefor; and optionally a non-liquid vaccine protection agent.

Abstract: A sustained release apparatus including at least one sustained release mini tablet implant; the or each mini tablet implant including a pharmaceutically active composition including at least one pharmaceutically active component; and a carrier therefor, wherein the or each tablet implant is of the coated tablet or covered rod type; the or each mini tablet implant being approximately 0.1 to 0.5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the pharmaceutical active selected, and having a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period; the sustained release apparatus providing, in use, zero order release of pharmaceutical active.

Abstract: A sustained release apparatus including at least one sustained release mini-implant or pellet; the or each mini-implant or pellet including: a sustained release support material; and a pharmaceutical composition including a Luteinising Hormone Releasing Hormone (HLRH) agonist and/or antagonist component the size and/or number and/or payload of mini-implant(s) or pellet(s) providing, release of LHRH agonist and/or antagonist at, or above, a desired threshold level for treatment of a selected indication, the apparatus providing approximately zero order release of the LHRH agonist and/or antagonist.

Abstract: A non-liquid vaccine composition including one or more antigen component(s); a pharmaceutically acceptable non-liquid adjuvant therefor; and optionally a non-liquid vaccine protection agent.

Abstract: A sustained release apparatus including at least one sustained release mini-implant or pellet; the or each mini-implant or pellet including: a sustained release support material; and a pharmaceutical composition including a Luteinising Hormone Releasing Hormone (HLRH) agonist and/or antagonist component the size and/or number and/or payload of mini-implant(s) or pellet(s) providing, release of LHRH agonist and/or antagonist at, or above, a desired threshold level for treatment of a selected indication, the apparatus providing approximately zero order release of the LHRH agonist and/or antagonist.

Abstract: A sustained release delivery apparatus including a silicone support material formed from a methyl-vinyl siloxane polymer including a fumed silica as a reinforcing filler; a pharmaceutically active composition carried in or on the silicone support material; the pharmaceutically active composition including at least one growth and/or reproduction-associated pharmaceutical component; analogue thereof or derivative thereof; and a carrier therefor.

Abstract: A sustained release mini-implant including a silicone support material; and a pharmaceutically active composition carried in or on the silicone support rod; the pharmaceutically active composition including at least one pharmaceutically active component; and optionally a carrier therefor; the mini-implant providing a predetermined threshold blood level of pharmaceutical active for treatment of a selected indication.

Abstract: An at least partially radio-opaque sustained release delivery apparatus including a sustained release support material; a pharmaceutically active composition carried in or on the sustained release support material; and a material which renders the delivery apparatus at least partially radio-opaque; the pharmaceutically active composition including at least one pharmaceutically active component; and optionally carrier therefor; the pharmaceutically active component being present in amounts of from approximately 30% to 75% by weight, based on the total weight of the sustained release delivery apparatus; the radio-opaque material being carried in the support material, and/or in the pharmaceutically active composition.

Abstract: A sustained release delivery apparatus including a silicone support material formed from a methyl-vinyl siloxane polymer including a fumed silica as a reinforcing filler; a pharmaceutically active composition carried in or on the silicone support material; the pharmaceutically active composition including at least one growth and/or reproduction-associated pharmaceutical component; analogue thereof or derivative thereof; and a carrier therefor.

Abstract: The use of an anti-parasitic agent in a sustained form in the treatment of ectoparasitic infections.

Abstract: A sustained release apparatus including at least one sustained release mini tablet implant; the or each mini tablet implant including a pharmaceutically active composition including at least one pharmaceutically active component; and a carrier therefor, wherein the or each tablet implant is of the coated tablet or covered rod type; the or each mini tablet implant being approximately 0.1 to 0.5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the pharmaceutical active selected, and having a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period; the sustained release apparatus providing, in use, zero order release of pharmaceutical active.

Abstract: A sustained release apparatus including a plurality of sustained release mini-implants or pellets; each mini-implant including a sustained release support material; and a pharmaceutically active composition carried in or on the sustained release support material; the pharmaceutically active composition including at least one pharmaceutically active component; and a carrier therefor; each implant being of insufficient size and/or payload individually to provide a predetermined desired threshold blood level of pharmaceutical active for treatment of a selected indication.

Abstract: A sustained release apparatus including a silicone support material; and a pharmaceutically active composition carried in or on the silicone support material; the pharmaceutically active composition including at least one pharmaceutically active component; and optionally a carrier therefor; the pharmaceutically active component being present in amounts of from approximately 30% to 75% by weight, based on the total weight of the sustained release apparatus.